Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe "golden dose" refers to the extra volume of medication visible at the tip of a used Mounjaro KwikPen after all four weekly doses have been administered — some patients notice it and wonder whether it can or should be used. The short answer is no. Each Mounjaro KwikPen is designed to deliver exactly four pre-set weekly doses; the small amount of liquid remaining afterwards is intentional overfill included by the manufacturer, Eli Lilly, to ensure the device reliably delivers each dose in full. Attempting to draw it out and inject it separately is not a safe or licensed use of the pen. If you are thinking about your Mounjaro dose, how it works, or whether your current dose is right for you, those are questions for your prescriber — not something to solve with a syringe. Mounjaro is a prescription-only medicine, and every aspect of its use, including dose, is determined through clinical assessment.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Open any forum discussing Mounjaro and you will eventually find someone asking about the liquid still visible in the pen tip after the fourth dose. People call it the "golden dose", the implication being that a usable injection is somehow being wasted. It is worth being clear about what that liquid actually is before anything else.
Eli Lilly designs the Mounjaro KwikPen with a small volume of overfill. This is standard pharmaceutical practice for injection devices: it ensures that the dose mechanism, the plunger, and the needle hub can each function correctly right through to the final injection. Without overfill, the fourth dose could be inconsistent or incomplete. So the residual liquid is not an accident, and it is not a bonus. It is a structural part of how the device works.
You can read more about how the pen itself functions, including the injection sequence, on our guide to using the golden dose pen correctly. The important thing here is simply this: the overfill was accounted for in the licensed dose and in every clinical trial that established Mounjaro's safety and effectiveness, including the SURMOUNT programme, which involved thousands of adults and whose results are published in the New England Journal of Medicine.
Yes, for several reasons that compound one another.
First, the volume is unknown. The pen is not calibrated to tell you how much liquid remains after the fourth dose, and it varies between units. You would be injecting an unmeasured amount of tirzepatide, which is not how the medicine has been tested or licensed. Tirzepatide's dose steps (2.5mg, 5mg, 7.5mg, and so on) are precise for a reason. The prescribing and titration schedule described in the Mounjaro Summary of Product Characteristics, available on the eMC, exists because the clinical evidence was gathered at those specific doses. An improvised fractional dose sits outside that evidence entirely.
Second, using a needle to draw liquid from a pen that has already been used introduces contamination risk. The pen tip and needle are single-use; reusing them or introducing a separate syringe risks infection at the injection site.
Third, and simply: this is not a licensed use of the medicine. The KwikPen is not a vial. It was not designed for dose extraction, and Eli Lilly does not sanction this approach. For a full look at what the 5mg pen specifically contains and how it is used within the licensed schedule, see our 5mg golden dose overview.
This is the real question underneath most "golden dose extraction" searches. The feeling that a dose is not doing enough, or that something is being left behind, is almost always a sign that the treatment needs a clinical review rather than a workaround.
Mounjaro is titrated through a structured schedule, treatment begins at 2.5mg, the starting strength designed to let your system settle, and is stepped upward by a prescriber based on tolerability and response. If the current dose feels insufficient, the right step is to discuss that with your prescriber at your next review. You can read about what this looks like in practice on our golden dose information page. Changing dose requires a clinical decision; it is not something the pen's residual liquid can substitute for.
If you are also asking about cost and whether there is a more affordable way to approach your treatment, our guide to Mounjaro pricing in the UK covers the landscape honestly. At nume, we are not the cheapest option available, and that is intentional. One price covers your consultation, prescription, and free next-working-day tracked delivery. No hidden extras.
A question our prescribers hear regularly: "Can I just top up my dose myself?" The answer, every time, is the same. Dose changes have to go through a prescriber. Our guide on how to take golden dose Mounjaro walks through the correct process so you understand exactly what the licensed approach involves. If your dose genuinely needs to change, that conversation takes minutes, and our page on a Mounjaro extra dose explains what that means clinically and why it requires a prescriber's involvement rather than a self-managed adjustment. Attempting to extract residual liquid from a spent pen takes longer, costs more in stress, and achieves nothing safe.
If you would like to explore your Mounjaro options with a real clinician, our prescribers are there. Speak to our prescribers through a free consultation and get a same-day clinical review of where you are in your treatment.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.